Search for a trial

Immune monitoring to characterize T-cell responses of kidney transplant patients during co-stimulation blockade by belatacept

Here, we postulate that the balance between the effect of belatacept on regulatory T-cell function and the relative insensitivity of memory T-cells for belatacept leads to donor-specific alloreactivity. We plan to study the peripheral CD28-dependent…

Cardiovascular (CV) risk prediction and CV biomarkers in renal transplant recipients treated with belatacept compared to calcineurin inhibitors (CNI).;Open randomized 12 month study.

The goal of this study is to prove whether kidney transplant recipients can reduce their risk of cardiovascular disease bij converting to Nulojix.

A Prospective, Open-label, Multicenter, Randomized Study to Evaluate the Benefits and Risks of
Conversion of Existing Adolescent Renal Allograft Recipients Aged 12 to Less Than 18 Years of
Age to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a
Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

This study has been transitioned to CTIS with ID 2022-501677-39-00 check the CTIS register for the current data. Evaluation of patient and functional graft survival of adolescent renal allograft recipients converted from CNI to belatacept-based…

Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix® (belatacept)-based Immunosuppression

Primary1. To evaluate patient and functional graft survival in stable renal transplant recipients (6-60 months post transplantation) converted from CNI to belatacept-based immunosupression as compared to those continuation of CNI based…